Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.

Bobardt M, Kuo J, Chatterji U, Chanda S, Little SJ, Wiedemann N, Vuagniaux G, Gallay PA.

PLoS One. 2019 Feb 4;14(2):e0211746. doi: 10.1371/journal.pone.0211746. eCollection 2019.

2.

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Bellaye PS, Oudot A, Vrigneaud JM, Raguin O, Bichat F, Vaslin A, Maby-El Hajjami H, Zanna C, Vuagniaux G, Fumoleau P, Denat F, Brunotte F, Collin B.

Contrast Media Mol Imaging. 2018 Dec 2;2018:8494031. doi: 10.1155/2018/8494031. eCollection 2018.

3.

DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.

Thibault B, Genre L, Le Naour A, Broca C, Mery E, Vuagniaux G, Delord JP, Wiedemann N, Couderc B.

Sci Rep. 2018 Dec 14;8(1):17862. doi: 10.1038/s41598-018-35860-z.

4.

SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.

Tao Z, McCall NS, Wiedemann N, Vuagniaux G, Yuan Z, Lu B.

Clin Cancer Res. 2019 Feb 1;25(3):1113-1124. doi: 10.1158/1078-0432.CCR-17-3852. Epub 2018 Oct 23.

PMID:
30352911
5.

HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial.

Cuypers L, Snoeck J, Kerremans L, Libin P, Crabbé R, Van Dooren S, Vuagniaux G, Vandamme AM.

Infect Genet Evol. 2016 Oct;44:169-181. doi: 10.1016/j.meegid.2016.06.050. Epub 2016 Jun 30.

PMID:
27374748
6.

A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome.

Yao J, Carter RA, Vuagniaux G, Barbier M, Rosch JW, Rock CO.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4264-73. doi: 10.1128/AAC.00535-16. Print 2016 Jul.

7.

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.

Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF.

Oncotarget. 2015 Nov 10;6(35):37410-25. doi: 10.18632/oncotarget.6138.

8.

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.

Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G, Bourhis J.

Radiother Oncol. 2015 Sep;116(3):495-503. doi: 10.1016/j.radonc.2015.05.017. Epub 2015 Jun 18.

PMID:
26096848
9.

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.

DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Sorensen JM, Zanna C.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):443-9. doi: 10.1016/j.clml.2015.02.020. Epub 2015 Mar 5.

10.

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.

Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C.

Cancer Chemother Pharmacol. 2015 Apr;75(4):851-9. doi: 10.1007/s00280-015-2709-8. Epub 2015 Feb 27.

11.

Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro.

Liu N, Tao Z, Blanc JM, Zaorsky NG, Sun Y, Vuagniaux G, Dicker AP, Lu B.

Am J Cancer Res. 2014 Nov 19;4(6):943-51. eCollection 2014.

12.

A near-full length genotypic assay for HCV1b.

Cuypers L, Snoeck J, Vrancken B, Kerremans L, Vuagniaux G, Verbeeck J, Nevens F, Camacho RJ, Vandamme AM, Van Dooren S.

J Virol Methods. 2014 Dec;209:126-35. doi: 10.1016/j.jviromet.2014.09.009. Epub 2014 Sep 22.

PMID:
25245140
13.

Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model.

Stenderup K, Rosada C, Gavillet B, Vuagniaux G, Dam TN.

Acta Derm Venereol. 2014 Nov;94(6):672-6. doi: 10.2340/00015555-1838.

14.

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B.

Viruses. 2013 Mar 22;5(3):981-97. doi: 10.3390/v5030981.

15.

Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.

de Wilde AH, Li Y, van der Meer Y, Vuagniaux G, Lysek R, Fang Y, Snijder EJ, van Hemert MJ.

J Virol. 2013 Feb;87(3):1454-64. doi: 10.1128/JVI.02078-12. Epub 2012 Nov 14.

16.

The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.

Quarato G, D'Aprile A, Gavillet B, Vuagniaux G, Moradpour D, Capitanio N, Piccoli C.

Hepatology. 2012 May;55(5):1333-43. doi: 10.1002/hep.25514. Epub 2012 Mar 18.

PMID:
22135208
17.

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J.

PLoS One. 2010 Oct 27;5(10):e13687. doi: 10.1371/journal.pone.0013687.

18.

Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells.

Prulière-Escabasse V, Clerici C, Vuagniaux G, Coste A, Escudier E, Planès C.

Respir Res. 2010 Oct 8;11:141. doi: 10.1186/1465-9921-11-141.

19.

Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice.

Wissing ER, Millay DP, Vuagniaux G, Molkentin JD.

Neuromuscul Disord. 2010 Nov;20(11):753-60. doi: 10.1016/j.nmd.2010.06.016. Epub 2010 Jul 15.

20.

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA.

J Hepatol. 2010 Jul;53(1):50-6. doi: 10.1016/j.jhep.2010.01.041. Epub 2010 Apr 3.

21.

Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025.

Landrieu I, Hanoulle X, Bonachera F, Hamel A, Sibille N, Yin Y, Wieruszeski JM, Horvath D, Wei Q, Vuagniaux G, Lippens G.

Biochemistry. 2010 Jun 8;49(22):4679-86. doi: 10.1021/bi1003266.

PMID:
20423153
22.

ENaC-mediated alveolar fluid clearance and lung fluid balance depend on the channel-activating protease 1.

Planès C, Randrianarison NH, Charles RP, Frateschi S, Cluzeaud F, Vuagniaux G, Soler P, Clerici C, Rossier BC, Hummler E.

EMBO Mol Med. 2010 Jan;2(1):26-37. doi: 10.1002/emmm.200900050.

23.

Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.

Delavallée L, Semerano L, Assier E, Vogel G, Vuagniaux G, Laborie M, Zagury D, Bessis N, Boissier MC.

Arthritis Res Ther. 2009;11(6):R195. doi: 10.1186/ar2897. Epub 2009 Dec 23.

24.

The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.

Tiepolo T, Angelin A, Palma E, Sabatelli P, Merlini L, Nicolosi L, Finetti F, Braghetta P, Vuagniaux G, Dumont JM, Baldari CT, Bonaldo P, Bernardi P.

Br J Pharmacol. 2009 Jul;157(6):1045-52. doi: 10.1111/j.1476-5381.2009.00316.x. Epub 2009 Jun 10.

25.

The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, Vuagniaux G, Parkinson T, Gallay P.

J Biol Chem. 2009 Jun 19;284(25):16998-7005. doi: 10.1074/jbc.M109.007625. Epub 2009 Apr 20.

26.

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C.

Crabbé R, Vuagniaux G, Dumont JM, Nicolas-Métral V, Marfurt J, Novaroli L.

Expert Opin Investig Drugs. 2009 Feb;18(2):211-20. doi: 10.1517/13543780802651583 . Review.

PMID:
19236267
27.

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J.

Antimicrob Agents Chemother. 2009 Mar;53(3):967-76. doi: 10.1128/AAC.00939-08. Epub 2008 Dec 22.

28.

Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.

Reutenauer J, Dorchies OM, Patthey-Vuadens O, Vuagniaux G, Ruegg UT.

Br J Pharmacol. 2008 Oct;155(4):574-84. doi: 10.1038/bjp.2008.285. Epub 2008 Jul 21.

29.

Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy.

Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J, Molkentin JD.

Nat Med. 2008 Apr;14(4):442-7. doi: 10.1038/nm1736. Epub 2008 Mar 16.

30.

Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice.

Gomez L, Thibault H, Gharib A, Dumont JM, Vuagniaux G, Scalfaro P, Derumeaux G, Ovize M.

Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1654-61. Epub 2007 Jun 8.

31.

A novel neutrophil elastase inhibitor prevents elastase activation and surface cleavage of the epithelial sodium channel expressed in Xenopus laevis oocytes.

Harris M, Firsov D, Vuagniaux G, Stutts MJ, Rossier BC.

J Biol Chem. 2007 Jan 5;282(1):58-64. Epub 2006 Nov 7.

32.

Activation of epithelial sodium channels by mouse channel activating proteases (mCAP) expressed in Xenopus oocytes requires catalytic activity of mCAP3 and mCAP2 but not mCAP1.

Andreasen D, Vuagniaux G, Fowler-Jaeger N, Hummler E, Rossier BC.

J Am Soc Nephrol. 2006 Apr;17(4):968-76. Epub 2006 Mar 8.

33.

In vitro and in vivo regulation of transepithelial lung alveolar sodium transport by serine proteases.

Planès C, Leyvraz C, Uchida T, Angelova MA, Vuagniaux G, Hummler E, Matthay M, Clerici C, Rossier B.

Am J Physiol Lung Cell Mol Physiol. 2005 Jun;288(6):L1099-109. Epub 2005 Jan 28.

34.

The transmembrane serine protease (TMPRSS3) mutated in deafness DFNB8/10 activates the epithelial sodium channel (ENaC) in vitro.

Guipponi M, Vuagniaux G, Wattenhofer M, Shibuya K, Vazquez M, Dougherty L, Scamuffa N, Guida E, Okui M, Rossier C, Hancock M, Buchet K, Reymond A, Hummler E, Marzella PL, Kudoh J, Shimizu N, Scott HS, Antonarakis SE, Rossier BC.

Hum Mol Genet. 2002 Nov 1;11(23):2829-36.

PMID:
12393794
36.

A conditional allele at the mouse channel activating protease 1 (Prss8) gene locus.

Rubera I, Meier E, Vuagniaux G, Mérillat AM, Beermann F, Rossier BC, Hummler E.

Genesis. 2002 Feb;32(2):173-6. No abstract available.

PMID:
11857812
37.

Activation of the amiloride-sensitive epithelial sodium channel by the serine protease mCAP1 expressed in a mouse cortical collecting duct cell line.

Vuagniaux G, Vallet V, Jaeger NF, Pfister C, Bens M, Farman N, Courtois-Coutry N, Vandewalle A, Rossier BC, Hummler E.

J Am Soc Nephrol. 2000 May;11(5):828-34.

Supplemental Content

Loading ...
Support Center